Institute for Cancer Research and Treatment , Candiolo, Turin, Italy.
J Vasc Interv Radiol. 2011 Dec;22(12):1714-20. doi: 10.1016/j.jvir.2011.09.001. Epub 2011 Oct 22.
To assess long-term clinical outcome of percutaneous vertebroplasty (PV).
PV was performed in 1,634 patients (1,387 women; median age 73 years ± 9.3) with painful osteoporotic vertebral compression fractures (VCFs). All patients had back pain that persisted for ≥ 2 months with a concordant magnetic resonance imaging study. After PV, medical therapy for osteoporosis was continued, and patients were prospectively evaluated (follow-up 11.8-44.9 months, mean 25.0 months). Visual analog scale (VAS), Oswestry Disability Index (ODI), analgesic drug use, and use of external brace support were recorded at baseline and during follow-up. New occurrences of symptomatic vertebral fractures were recorded.
The mean VAS score of 7.94 significantly improved to 1.12 at the primary endpoint (P < .001). Differences in patterns of analgesic usage compared with baseline values were highly statistically significant (marginal homogeneity test, P < .001). Median ODI values of 82% before treatment significantly decreased to 6% (P < .001). Before intervention, 1,279 patients wore a brace; 1,167 (91.2%) patients did not wear a brace after PV (χ(2) = 31.005, P < .0001). A new painful fracture with a significant higher proportion of contiguous vertebrae (63.6%) occurred in 214 (13.1%) patients (z = 7.59, P = .025).
PV can provide durable pain relief and improvement in ambulation in patients with VCFs.
评估经皮椎体成形术(PV)的长期临床疗效。
对 1634 例(1387 例女性;中位年龄 73 岁±9.3 岁)因骨质疏松性椎体压缩性骨折(VCF)导致疼痛的患者进行了 PV。所有患者均有持续≥2 个月的背痛,并伴有一致的磁共振成像研究。PV 后,继续进行骨质疏松症的药物治疗,并对患者进行前瞻性评估(随访 11.8-44.9 个月,平均 25.0 个月)。记录基线和随访时的视觉模拟量表(VAS)、Oswestry 残疾指数(ODI)、镇痛药使用情况和外部支撑带的使用情况。记录新发生的有症状椎体骨折。
7.94 的平均 VAS 评分在主要终点显著改善至 1.12(P<.001)。与基线值相比,镇痛药使用模式的差异具有高度统计学意义(边缘同质性检验,P<.001)。治疗前 ODI 中位数为 82%,显著降低至 6%(P<.001)。干预前,1279 例患者佩戴支具;1167 例(91.2%)患者在 PV 后不佩戴支具(χ(2) = 31.005,P<.0001)。214 例(13.1%)患者发生新的疼痛性骨折,且相邻椎体的比例明显更高(63.6%)(z = 7.59,P =.025)。
PV 可提供持久的疼痛缓解,并改善 VCF 患者的活动能力。